Pharmacom Biovet Key Fundamental Indicators
| PHMB Stock | USD 0.0001 0.00 0.00% |
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pharmacom Biovet, as well as the relationship between them.
Pharmacom Biovet's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pharmacom Biovet's valuation are provided below:Market Capitalization 1.1 M |
Pharmacom | Select Account or Indicator | Build AI portfolio with Pharmacom Stock |
Pharmacom Biovet Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacom Biovet Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacom Biovet Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacom Biovet. Anticipated expansion of Pharmacom directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pharmacom Biovet assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Pharmacom Biovet's market price often diverges from its book value, the accounting figure shown on Pharmacom's balance sheet. Smart investors calculate Pharmacom Biovet's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Pharmacom Biovet's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Pharmacom Biovet's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pharmacom Biovet should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Pharmacom Biovet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Pharmacom Biovet 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pharmacom Biovet's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pharmacom Biovet.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Pharmacom Biovet on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Pharmacom Biovet or generate 0.0% return on investment in Pharmacom Biovet over 90 days. Pharmacom Biovet is related to or competes with Cyduct Diagnostics, DATATRAK International, Escalon Medical, and Ligand Pharmaceuticals. PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States More
Pharmacom Biovet Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pharmacom Biovet's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pharmacom Biovet upside and downside potential and time the market with a certain degree of confidence.
Pharmacom Biovet Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharmacom Biovet's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pharmacom Biovet's standard deviation. In reality, there are many statistical measures that can use Pharmacom Biovet historical prices to predict the future Pharmacom Biovet's volatility.Pharmacom Biovet Backtested Returns
We have found three technical indicators for Pharmacom Biovet, which you can use to evaluate the volatility of the company. The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Pharmacom Biovet are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Pharmacom Biovet has perfect predictability. Overlapping area represents the amount of predictability between Pharmacom Biovet time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pharmacom Biovet price movement. The serial correlation of 1.0 indicates that 100.0% of current Pharmacom Biovet price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Pharmacom Biovet has a Current Valuation of 1.08 M. This is 99.99% lower than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Pharmacom Biovet Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pharmacom Biovet's current stock value. Our valuation model uses many indicators to compare Pharmacom Biovet value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharmacom Biovet competition to find correlations between indicators driving Pharmacom Biovet's intrinsic value. More Info.Pharmacom Biovet is rated below average in current valuation category among its peers. It is considered to be number one stock in net income category among its peers . At present, Pharmacom Biovet's Net Loss is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharmacom Biovet's earnings, one of the primary drivers of an investment's value.Pharmacom Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmacom Biovet's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharmacom Biovet could also be used in its relative valuation, which is a method of valuing Pharmacom Biovet by comparing valuation metrics of similar companies.Pharmacom Biovet is currently under evaluation in current valuation category among its peers.
Pharmacom Fundamentals
| Current Valuation | 1.08 M | ||||
| Net Income | (556.18 K) | ||||
| Total Debt | 61.54 K | ||||
| Beta | 168.8 | ||||
| Market Capitalization | 1.08 M | ||||
| Total Asset | 112.36 K | ||||
| Retained Earnings | (19.05 M) | ||||
| Working Capital | (29 K) | ||||
| Current Liabilities | 29 K | ||||
| Net Asset | 112.36 K |
About Pharmacom Biovet Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmacom Biovet's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmacom Biovet using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmacom Biovet based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pharmacom Biovet offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pharmacom Biovet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacom Biovet Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacom Biovet Stock:Check out For information on how to trade Pharmacom Stock refer to our How to Trade Pharmacom Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacom Biovet. Anticipated expansion of Pharmacom directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pharmacom Biovet assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Pharmacom Biovet's market price often diverges from its book value, the accounting figure shown on Pharmacom's balance sheet. Smart investors calculate Pharmacom Biovet's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Pharmacom Biovet's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Pharmacom Biovet's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pharmacom Biovet should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Pharmacom Biovet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.